RNAi and RNA Reagents Market Size, Share, and Industry Analysis, By Product (siRNA Controls, RNAi Controls, miRNA, RNAi Screening Libraries, and Others), By Application (Therapeutics, Research, Drug Discovery, and Others), By End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI114805

RNAi and RNA Reagents Market Overview

The global RNAi and RNA reagents market is witnessing significant growth. The market growth is driven by an increase in research and development activities, particularly for novel and innovative drug development by leading pharmaceutical companies. Additionally, the rise in prevalence of genetic disorders increases the demand for effective and targeted treatment options based on RNAi therapies, further supporting the market growth. Moreover, strategic collaborations between key pharmaceutical companies are expected to boost the market growth.

For instance, in June 2020, Sirnaomics Inc. partnered with Precision NanoSystems Inc. for the development and manufacturing of Sirnaomics' polypeptide nanoparticle-based RNAi therapeutic product. Such partnerships increase the RNAi and RNA reagents demand and support the market growth.

RNA interference (RNAi) is a natural process for the regulation of protein synthesis and immunity. It is a potent tool for the exploration and manipulation of gene expression.

RNAi and RNA Reagents Market Driver

Increase in Research & Development Activities on RNA-based Therapeutics Drives Market Growth

The global RNAi and RNA reagents market is experiencing substantial growth, primarily driven by the rise in research and development (R&D) activities, especially in RNA interference (RNAi) and other RNA-based therapeutics. The rise in investment in the R&D sector and advancement in RNA synthesis and delivery technologies boost the R&D activities and drive the market growth. Additionally, the rise in incidence of chronic diseases drives the demand for new and effective treatments, including RNA-based therapies, and supports the market growth.

For instance, in June 2023, Flamingo Therapeutics received USD 1.8 million from VLAIO for the advancement of its RNA-targeting oncology portfolio. Such types of investments increase R&D activities and boost the market growth.

Global RNAi Therapies in Pipeline (in %), 2024

According to the data published by the American Society of Gene & Cell Therapy (ASGCT) in 2024, 73.0% of RNAi therapies are in the preclinical phase and 27.0% are in the clinical phase.

RNAi and RNA Reagents Market Restraint

Potential Safety Concerns May Hinder the Market Growth

Potential safety concerns, such as immunogenicity, toxicity, and off-target effects, may hinder the growth of the RNAi and RNA reagents market. These concerns are expected to show adverse effects on patients, complicate clinical trials, and create regulatory hurdles, potentially impacting the market growth. RNA reagents, especially synthetic ones, such as siRNA, can be recognized by the immune system as foreign material and trigger an immune response that can cause inflammation. In this scenario, the product adoption rate is expected to be low, which hinders the market growth.

For instance, according to the data published by Horizon Discovery, a company offering products in this market space, the toxicity arises from off-target effects, where RNAi reagents inadvertently target and silence unintended transcripts due to partial sequence complementarity.

RNAi and RNA Reagents Market Opportunity

Rise in Usage of RNAi Reagents in Therapeutics Expected to Offer Lucrative Growth Opportunities in the Future

The rise in the use of RNA interference (RNAi) and RNA reagents in therapeutics is expected to offer lucrative growth opportunities during the forecast period. This is due to these reagents having the potential to treat diseases caused by proteins that are difficult to target with conventional drugs. Additionally, the development of personalized medicine raises the usage of RNAi reagents in therapeutics, which is expected to offer growth opportunities in the future. The RNAi reagents have the potential to design and deliver the specific molecules to silence disease-causing genes, making it a powerful reagent for personalized medicine. The pharmaceutical companies are actively focusing on developing RNAi therapeutics, which are expected to increase demand and provide growth opportunities to the market.

For instance, in March 2025, Alnylam Pharmaceuticals, Inc. received the U.S. FDA approval for the First siRNA (RNAi Therapeutic) for Hemophilia A or B.

Key Insights

The report covers the following key insights:

Pipeline Analysis- RNAi Therapies, By Key Players
New Product Launches, By Key Players
Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

By Product	By Application	By End-user	By Region
siRNA Controls RNAi Controls miRNA RNAi Screening Libraries Others	Therapeutics Research Drug Discovery Others	Pharmaceutical and Biotechnology Companies Academic and Research Institutes Others	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Analysis by Product

By product, the market is divided into siRNA Controls, RNAi Controls, miRNA, RNAi Screening Libraries, and others.

The siRNA controls segment accounted for a significant revenue share in the market. This growth is due to its advantages, such as high specificity, potency, and flexibility, and highly accurate results. siRNA also plays an important role in research by validating gene silencing experiments and ensuring accurate results. Additionally, siRNA controls have potential for targeting novel diseases, which increases the segment growth in the market.

For instance, according to the data published by Revvity Discovery Limited, siRNA is the novel pathways, which have a significant impact on validating targets for several cellular processes and diseases, such as HIV infection and cancer.

Analysis by Application

On the basis of application, the market is segmented into therapeutics, research, drug discovery, and others.

The therapeutics segment held a substantial share of the global RNAi and RNA reagents market in 2024. The segment growth is attributed to the rise in regulatory approvals for RNA-based therapeutics. Additionally, advancements in RNAi delivery systems and an increase in research funding support the therapeutics segment growth.

For instance, in December 2021, Novartis AG received approval from the U.S. FDA for Leqvio, a first-in-class siRNA to lower bad cholesterol.

Analysis by End-user

According to the end user segment, the market is classified into the pharmaceutical and biotechnology companies, academic and research institutes, and others.

The pharmaceutical & biotechnology companies segment held a significant portion of the market. The growth of the segment is attributed to their strong focus on research activity for the development of novel therapies with the help of RNAi and RNA reagents. Additionally, strategic initiatives by the pharmaceutical company also support the segment's growth.

For instance, according to the data published by Alnylam Pharmaceuticals, Inc., a leading player in RNAi therapeutics, it has a robust pipeline of investigational RNAi therapeutics.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization to gain extensive market insights.

North America accounted for a substantial share of the global RNAi and RNA reagents market in 2024. This is due to the high concentration of research institutions and universities, which are actively engaged in RNA and RNAi reagent research. Additionally, government support and the strong presence of pharmaceutical and biotechnology industries in this region also support the market growth.

For instance, according to the data published by the Government of Canada, in February 2024, Laval businesses received USD 2,00,000 from Canada Economic Development for Quebec Regions (CED) for the advancement in RNA technologies & therapeutics.

Europe has a significant share of the global RNAi and RNA reagents market. The growth of the region can be attributed to a rise in focus on personalized medicine and targeted therapies. Additionally, the European research institutes, such as the Center for Genomic Regulation (CRG) and the National Center for Biotechnology (CNB), are actively involved in RNAi research, which is expected to boost the market growth in this region.

Asia Pacific is the fastest-growing region during the forecast period. The rise in investment in the research and development sector and the growing pharmaceutical industry support the market growth in this region.

Key Players Covered

The global RNAi and RNA reagents market is fragmented, with a few key players. The report includes the profiles of the following key players:

Thermo Fisher Scientific Inc. (U.S.)
Revvity (U.S.)
OriGene Technologies, Inc. (U.S.)
Merck KGaA (Germany)
Bio-Rad Laboratories, Inc. (U.S.)
Creative Biogene (U.S.)

Key Industry Developments

In September 2023, GenScript expanded its range of reagents by adding an IVT mRNA synthesis portfolio with customized circular RNA (circRNA) and lipid nanoparticles.
In February 2023, Myeloid Therapeutics was selected for the RNA research and pilot manufacturing plant management at Macquarie University in Sydney, Australia.